


Product: Elacridar

ALTERNATE NAME: N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide;GF120918; GG 918; GW0918; GF-120918)

CATALOG #: 2792-5, 25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₃₄H₃₃N₃O₅

MOLECULAR WEIGHT: 563.64

CAS NUMBER: 143664-11-3

APPEARANCE: Yellow solid

SOLUBILITY: DMSO (~2 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: Store at -20°C. Protect from air and light

DESCRIPTION: Elacridar is a potent P-glycoprotein (P-gp/ABCG1) and breast cancer resistance protein (BCRP) inhibitor. GF120918 increases the bioavailability of cytotoxic anti-tumor drugs, and also leads to increased levels of anti-HIV drugs in the brain and CNS.

REFERENCES: Hyafil F., *et al.* (1993). *Cancer Res.* **53**, 4595-4602.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

MK-571 (Cat. No. 2691-5, 25)

MK-571, sodium salt (Cat. No. 2692-5, 25)

NSC-23925 (Cat. No. 2686-5, 25)

FOR RESEARCH USE ONLY! Not to be used on humans.